Please ensure Javascript is enabled for purposes of website accessibility

Why Supernus Pharmaceuticals Plunged 15% Today

By Brian Feroldi - Feb 26, 2020 at 5:59PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares slumped after the commercial-stage biopharma reported mixed results.

What happened

In response to the company announcing mixed fourth-quarter results and issuing weak guidance, shares of Supernus Pharmaceuticals (SUPN 1.47%), a biopharma focused on diseases of the central nervous system, slumped 15% on Wednesday.

So what

The headline numbers for the quarter were mixed:

  • Fourth-quarter net product sales dropped 15% to $97.9 million. Management said that sales in the year-ago quarter were $10 million higher than they would have been otherwise due to inventory building at wholesalers and distributors. Pricing pressure also acted as a drag on sales.
  • Total revenue fell 15% to $100.4 million. That was several million dollars worse than what Wall Street was expecting. 
  • Net income was $33.1 million, or $0.62 per share. That was a 29% jump when compared to the year-ago period, and was $0.02 above the consensus estimate.
Man in business suit with a big thumb pointing down

Image source: Getty Images.

In other news, the FDA has accepted Supernus' New Drug Application for SPN-812 as a potential treatment for ADHD. A target action date of Nov. 8, 2020, has been set. The company plans to launch the drug in the fourth quarter of 2020 if everything goes according to plan.

Meanwhile, management decided to halt all development activities of a compound called SPN-810 after the drug failed to produce the desired result in a phase 3 trial. 

Supernus CEO Jack Khattar commented:

With our NDA for SPN-812 in ADHD accepted for review by the FDA, we continue to prepare the Company for the commercial launch of SPN-812 and look forward to bringing this important new treatment option to patients and physicians. If approved by the FDA, SPN-812 has the potential of becoming the first novel treatment to be introduced in the ADHD market in more than a decade.

For 2020, management believes that net product sales will range between $360 million and $390 million. The midpoint of that range is well below the $407.7 million in revenue that Wall Street was looking for.

Given the weak quarterly revenue and guidance for 2020, it's not surprising to see Supernus shares taking a big step back today. 

Now what

2019 was certainly a disappointing year for Supernus, but some analysts believe that SPN-812 holds hundreds of millions of dollars in peak sales potential. If the drug can win FDA approval later this year, it could be a major positive catalyst for this beaten-down biopharma.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Supernus Pharmaceuticals, Inc. Stock Quote
Supernus Pharmaceuticals, Inc.
SUPN
$28.92 (1.47%) $0.42

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
317%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.